drugset
Drugs / ADCE-D01
last change Apr 2026 re-read 3 minutes ago

ADCE-D01

Developed for
soft tissue sarcoma
Investigated by
Adcendo ApS

Trials 1

today NCT06797999 · Ph 1/2
2026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06797999 Jun 2025 → Feb 2029 expected soft tissue sarcoma Adcendo ApS Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 4

DateIssuerRelease
2026-04-20 Adcendo ApS Regulatory Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates adcendo.com ↗
ADCE-D01, a first-in-class uPARAP targeted ADC, granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA)
2025-10-09 Adcendo ApS Regulatory Adcendo ApS Announces FDA Fast Track Designation Granted to ADCE-D01 for the Treatment of Soft Tissue Sarcoma adcendo.com ↗
2025-04-23 Adcendo ApS Results Adcendo ApS to Present Data on its Clinical Stage ADCs ADCE-T02 and ADCE-D01 at the 2025 American Association for Cancer Research (AACR) Annual Meeting adcendo.com ↗
ADCE-D01 – a first-in-class ADC against urokinase plasminogen activator receptor-associated protein (uPARAP) – demonstrates excellent preclinical efficacy and tolerability
2024-10-08 Adcendo ApS Regulatory Adcendo Announces US FDA Clearance of IND Application for Phase I/II First-in-Human ADCElerate-01 Trial of ADCE-D01 (uPARAP Receptor Targeting ADC) Trial in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma (STS) adcendo.com ↗

All press releases naming this drug 5 releases

DateIssuerRelease

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ADCE-D01 “ADCE-D01 is an antibody-drug conjugate (ADC) composed of an anti-urokinase plasminogen activator receptor-associated protein (uPARAP) antibody, AB-004, conjugated to a...” NCT06797999 ↗